ATE277633T1 - Präparate und verfahren zum auslösen von ctl- immunität - Google Patents
Präparate und verfahren zum auslösen von ctl- immunitätInfo
- Publication number
- ATE277633T1 ATE277633T1 AT95910309T AT95910309T ATE277633T1 AT E277633 T1 ATE277633 T1 AT E277633T1 AT 95910309 T AT95910309 T AT 95910309T AT 95910309 T AT95910309 T AT 95910309T AT E277633 T1 ATE277633 T1 AT E277633T1
- Authority
- AT
- Austria
- Prior art keywords
- ctl
- response
- triggering
- preparations
- methods
- Prior art date
Links
- 230000036039 immunity Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/197,484 US6419931B1 (en) | 1991-08-26 | 1994-02-16 | Compositions and methods for eliciting CTL immunity |
| PCT/US1995/002121 WO1995022317A1 (en) | 1994-02-16 | 1995-02-16 | Compositions and methods for eliciting ctl immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE277633T1 true ATE277633T1 (de) | 2004-10-15 |
Family
ID=22729600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95910309T ATE277633T1 (de) | 1994-02-16 | 1995-02-16 | Präparate und verfahren zum auslösen von ctl- immunität |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6419931B1 (de) |
| EP (1) | EP0804158B1 (de) |
| AT (1) | ATE277633T1 (de) |
| AU (1) | AU1847395A (de) |
| CA (1) | CA2183416A1 (de) |
| DE (1) | DE69533594T2 (de) |
| WO (1) | WO1995022317A1 (de) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| US7611713B2 (en) * | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
| US6689363B1 (en) | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| US20110097352A9 (en) * | 1992-01-29 | 2011-04-28 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| IL105554A (en) * | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| WO1995004542A1 (en) * | 1993-08-06 | 1995-02-16 | Cytel Corporation | Cloning and characterization of the complete mage-1 gene |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
| AU712441B2 (en) * | 1994-12-14 | 1999-11-04 | Scripps Research Institute, The | In vivo activation of tumor-specific cytotoxic T cells |
| US6514942B1 (en) * | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| AUPN568095A0 (en) * | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| FR2776926B1 (fr) * | 1998-04-07 | 2003-10-24 | Inst Nat Sante Rech Med | Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination |
| US20010019714A1 (en) * | 1998-04-07 | 2001-09-06 | Charles D. Y. Sia | Hiv-specific cytotoxic t-cell responses |
| US6534482B1 (en) * | 1998-05-13 | 2003-03-18 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| JP2003509465A (ja) * | 1999-07-19 | 2003-03-11 | エピミューン, インコーポレイテッド | ペプチドおよび核酸組成物を使用する、c型肝炎ウイルスに対する細胞性免疫応答の誘導 |
| US20030235594A1 (en) * | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US9289487B2 (en) * | 1999-09-14 | 2016-03-22 | Antigen Express, Inc. | II-key/antigenic epitope hybrid peptide vaccines |
| US6432409B1 (en) * | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
| US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
| AU7917200A (en) * | 1999-09-30 | 2001-04-30 | Institut Pasteur | Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences |
| EP1225907A4 (de) * | 1999-10-05 | 2005-06-22 | Epimmune Inc | Induktion zellulärer immunantworten gegen humanes immundefiziens virus-1 (hiv-1) mittels peptid- und nukleinsäureverbindungen |
| EP2177534A3 (de) * | 1999-11-18 | 2010-07-14 | Pharmexa Inc. | Heteroklitische Analoga von Klasse-i Epitopen |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| CA2393339A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| US20040248113A1 (en) * | 1999-12-28 | 2004-12-09 | Alessandro Sette | Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| EP1195381A1 (de) | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
| EP2371854B1 (de) * | 2001-03-09 | 2014-05-07 | Board Of Regents, The University Of Texas System | Einleitung von Tumorimmunität durch Varianten eines folatbindenden Protein |
| US20040202654A1 (en) | 2001-04-09 | 2004-10-14 | Mayo Foundation For Medical Education & Research | Methods and materials for cancer treatment |
| US7842480B2 (en) * | 2001-05-18 | 2010-11-30 | Mayo Foundation For Medical Education And Research | Chimeric antigen-specific t cell-activating polypeptides |
| US20060222656A1 (en) * | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| CA2481462A1 (en) * | 2002-04-05 | 2003-10-23 | Epimmune Inc. | Heteroclitic analogs and related methods |
| US20050181459A1 (en) * | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
| EP1537418A2 (de) | 2002-09-13 | 2005-06-08 | Intercell AG | Verfahren zur isolierung von hepatitis c virus peptiden |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| EP1408048A1 (de) * | 2002-10-07 | 2004-04-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Impfstoffe mit erhöhter Immunogenität und Methoden zur deren Herstellung |
| US20040072262A1 (en) * | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| WO2004084805A2 (en) * | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
| AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| WO2005012502A2 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| WO2005033265A2 (en) * | 2003-04-25 | 2005-04-14 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| CA2530062A1 (en) | 2003-07-11 | 2005-01-20 | Intercell Ag | Hcv vaccines |
| IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| US7304139B2 (en) * | 2003-10-28 | 2007-12-04 | University Of Florida Research Foundation, Inc. | Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same |
| WO2005047902A1 (en) * | 2003-11-03 | 2005-05-26 | Beckman Coulter, Inc. | Solution-based methods for detecting mhc-binding peptides |
| US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| EP1766393A4 (de) * | 2004-05-07 | 2008-06-18 | Beckman Coulter Inc | Mhc-brückensystem zum nachweis der ctl-vermittelten lyse antigenpräsentierender zellen |
| EP2226332A1 (de) * | 2004-06-17 | 2010-09-08 | Beckman Coulter, Inc. | Mycobacterium-tuberculosis-Epitope und Verfahren zu deren Verwendung |
| WO2006085141A2 (en) * | 2004-08-13 | 2006-08-17 | Migenix Inc. | Compositions and methods for treating or preventing hepadnaviridae infection |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| CN101291683B (zh) * | 2004-11-24 | 2011-08-17 | 纽普罗研究有限公司 | 治疗疾病的方法和组合物 |
| CA2592922A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| EP1764369A1 (de) * | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
| JP5133706B2 (ja) * | 2006-01-23 | 2013-01-30 | 株式会社グリーンペプタイド | C型肝炎ウイルス由来ペプチド |
| CA2647835A1 (en) * | 2006-03-28 | 2007-10-04 | Neopro Labs, Llc | Methods and compositions for treating conditions |
| AR064500A1 (es) * | 2006-12-22 | 2009-04-08 | Dow Agrosciences Llc | Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas |
| US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| EP2152725A1 (de) | 2007-05-17 | 2010-02-17 | Neopro Labs, LLC | Kristalline und amorphe peptidformen |
| EP2468763B1 (de) * | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV-Epitope als Ziel für zervikale Tumoren infiltrierende T-Zellen zur Verwendung bei Impfstoffen |
| JP2010530362A (ja) | 2007-05-31 | 2010-09-09 | アカデミシュ ジーケンハウス ライデン ハー.オー.デー.エン. ルムク | 皮内hpvペプチドワクチン接種 |
| WO2009012472A2 (en) * | 2007-07-18 | 2009-01-22 | Neopro Labs, Llc | Methods and compositions for treating conditions |
| US8466259B2 (en) | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
| TWI376385B (en) | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
| AU2009236306B2 (en) * | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| EP2391635B1 (de) | 2009-01-28 | 2017-04-26 | Epimmune Inc. | Pan-dr-bindende polypeptide und verwendungen davon |
| CN108373509A (zh) * | 2009-03-10 | 2018-08-07 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| US8287880B2 (en) | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
| US8658176B2 (en) * | 2009-06-22 | 2014-02-25 | National Health Research Institutes | Lipidated tumor-associated antigens and immunotherapeutic compositions |
| WO2012027379A2 (en) | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| WO2013173411A1 (en) | 2012-05-16 | 2013-11-21 | Stemline Therapeutics, Inc | Cancer stem cell targeted cancer vaccines |
| US10286064B2 (en) | 2012-06-15 | 2019-05-14 | Pds Biotechnology Corporation | Cationic lipid vaccine compositions and methods of use |
| AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| TW201924722A (zh) | 2017-12-05 | 2019-07-01 | 美商Pds生技公司 | 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物 |
| EP3909612A1 (de) * | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Zusammensetzung von nanopartikeln |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2480779B2 (fr) | 1979-08-30 | 1986-07-18 | Anvar | Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur |
| US4935235A (en) | 1979-05-24 | 1990-06-19 | The Regents Of The University Of California | Non-passageable viruses |
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US5017558A (en) | 1980-01-14 | 1991-05-21 | The Regents Of The University Of California | Synthetic vaccine peptide epitomes of hepatitis B surface antigen |
| US4487715A (en) | 1982-07-09 | 1984-12-11 | The Regents Of The University Of California | Method of conjugating oligopeptides |
| EP0105481A1 (de) | 1982-09-30 | 1984-04-18 | The Wellcome Foundation Limited | Antigene und diese enthaltende Vakzine |
| JPS60161999A (ja) | 1984-02-02 | 1985-08-23 | Chemo Sero Therapeut Res Inst | ペプチド |
| US4599230A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| JPS6137738A (ja) | 1984-07-31 | 1986-02-22 | Tetsuo Nakamura | B型肝炎ワクチン |
| DE3937412A1 (de) | 1989-11-10 | 1991-05-16 | Hoechst Ag | Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten |
| US4882145A (en) | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| US4818527A (en) * | 1986-12-09 | 1989-04-04 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5030449A (en) * | 1988-07-21 | 1991-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthetic vaccine against AIDS virus |
| US5128319A (en) * | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| US5013548A (en) | 1987-09-08 | 1991-05-07 | Duke University | Production of antibodies to HIV |
| US4900547A (en) * | 1987-10-23 | 1990-02-13 | University Of British Columbia | Method to immunize mammals against tumors |
| US5039522A (en) | 1988-01-29 | 1991-08-13 | New York Blood Center, Inc. | Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen |
| IT1238343B (it) | 1989-10-16 | 1993-07-13 | Cesalpino Andrea Fond | Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche |
| GB8924438D0 (en) | 1989-10-31 | 1989-12-20 | Hoffmann La Roche | Vaccine composition |
| US5155210A (en) * | 1990-09-11 | 1992-10-13 | Brunswick Corporation | Methods of conjugating actinomycin d |
| DE69231621T2 (de) | 1991-08-26 | 2001-05-31 | Epimmune, Inc. | Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons |
| IL105554A (en) * | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
| US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| SG49008A1 (en) * | 1993-03-05 | 1998-05-18 | Cytel Corp | Hla-a2.1 binding peptides and their uses |
-
1994
- 1994-02-16 US US08/197,484 patent/US6419931B1/en not_active Expired - Lifetime
-
1995
- 1995-02-16 AT AT95910309T patent/ATE277633T1/de not_active IP Right Cessation
- 1995-02-16 WO PCT/US1995/002121 patent/WO1995022317A1/en not_active Ceased
- 1995-02-16 AU AU18473/95A patent/AU1847395A/en not_active Abandoned
- 1995-02-16 CA CA002183416A patent/CA2183416A1/en not_active Abandoned
- 1995-02-16 EP EP95910309A patent/EP0804158B1/de not_active Expired - Lifetime
- 1995-02-16 DE DE69533594T patent/DE69533594T2/de not_active Expired - Fee Related
-
2002
- 2002-04-22 US US10/128,711 patent/US20030099634A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2183416A1 (en) | 1995-08-24 |
| AU1847395A (en) | 1995-09-04 |
| DE69533594D1 (de) | 2004-11-04 |
| EP0804158A1 (de) | 1997-11-05 |
| EP0804158B1 (de) | 2004-09-29 |
| DE69533594T2 (de) | 2006-02-16 |
| US6419931B1 (en) | 2002-07-16 |
| WO1995022317A1 (en) | 1995-08-24 |
| EP0804158A4 (de) | 1999-05-12 |
| US20030099634A1 (en) | 2003-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533594D1 (de) | Präparate und verfahren zum auslösen von ctl-immunität | |
| ES2141750T5 (es) | Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno. | |
| DK1104306T3 (da) | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf | |
| KR890701125A (ko) | 무병원성 미생물 및 이의 용도 | |
| CA2123580A1 (en) | Antigen of hybrid m protein and carrier for group a streptococcal vaccine | |
| ATE422352T1 (de) | Liposomaler grippeimpfstoff und verfahren | |
| IL114444A (en) | Kit for inducing immune response against a tumor or a disease caused by an infectious agent | |
| CA2185470A1 (en) | Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes | |
| CA2231603A1 (en) | Chicken interleukin-15 and uses thereof | |
| EP1239876A4 (de) | Impfstoff zusammensetzungen | |
| FI851859A0 (fi) | Antigenpreparat och isolering av saodana preparat. | |
| Ciupitu et al. | Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses | |
| Ahlert et al. | Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns | |
| WO2001079259A8 (en) | Javelinization of protein antigens to heat shock proteins | |
| Lian et al. | Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses | |
| WO2002051237A3 (en) | Helicobacter proteins, nucleic acids and uses thereof | |
| WO2004033483A3 (en) | Liposomal system and method of using same | |
| CA2133108A1 (en) | Pasteurella haemolytica type a-1 bacterin-toxoid vaccine | |
| IL149415A0 (en) | Adjuvanted genetic vaccines | |
| DE69322960D1 (de) | Empfängnisverhütender impfstoff | |
| Morein et al. | Initiation of immune response with ISCOM | |
| Koprowski et al. | Anti-idiotype vaccines against viral infections | |
| AU8501191A (en) | Cross-reactive influenza a immunization | |
| AU2579600A (en) | Product and method for obtaining specific immunisation with one or more antigens | |
| EP0320034A3 (de) | Synthetische Peptide, die immunologische Aktivität zeigen, benutzbar, um eine Impfung gegen Malaria vorzubereiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |